We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Katherine
Payne
katherine.payne@manchester.ac.uk
Dr
JI HEE
YOUN
jihee.youn@manchester.ac.uk
General symptoms and signs
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
Studies that generate evidence of relative cost-effectiveness of new medicines are a vital input when producing clinical guidelines or conduct technology appraisal by bodies such as the National Institute for Health and Care Excellence (NICE). Such analyses should capture the impact of all the relevant costs, benefits and harms of the intervention under evaluation. Some aspect of the harms from a medicine is usually already incorporated to at least some extent by including a negative impact on health status (disutility) associated with adverse drug reactions (ADRs). There is growing evidence that suggests that taking a specific treatment, particularly one requiring long-term use for a chronic condition, can cause inconvenience or “disutility” to a patient which is exclusive to the unwanted harms, adverse outcomes or effects from an intervention. The concept of Direct Treatment Disutility (DTD) is over and above the disutility (harm) captured by attaching a negative value associated with ADRs or the financial cost of out-of-pocket costs for the patient. The negative impact of taking a medicine for life, especially a preventative medicine with no obvious immediate benefits, is currently ignored in cost-effectiveness analysis. In a previous study, it was identified that even very low plausible levels of DTD could significantly reduce or even reverse expected relative cost-effectiveness of a statin treatment. There is an emerging literature in this field but there is a need to better estimate how large DTD actually is and the variation in elicited DTD values. This study will use qualitative (think aloud) and survey-based (time trade-off and best worst scaling) methods to identify and measure the impact of DTD associated with taking medicines for prevention of selected conditions (statin to prevent heart disease; bisphosphonate to prevent bone loss). The study will include the values from patients taking these medicines and the general public.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
This study will use two study samples. Inclusion criteria for patients with experience of taking a medicine: • Aged 30 years or over; • Has been prescribed a bisphosphonate (British National Formulary (BNF) category 060602) in the last year; • Has been prescribed a statin (statins selected from BNF 0212, HIC expanded BNF 021201) in the last year. Inclusion criteria for members of the public: • Aged 30 years or over
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Manchester and funded by NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 34736
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
